The Phase 3 HIBISCUS study (NCT04624659) investigating etavopivat in adults and adolescents with Sickle Cell Disease reached its primary completion on 2026-02-06. This milestone indicates that the final data for the primary outcome measures have been collected, moving the trial closer to results analysis.
Background
Sickle Cell Disease is a genetic blood disorder characterized by abnormally shaped red blood cells that can block blood flow, leading to pain crises (vaso-occlusive crises), anemia, and other serious complications. The HIBISCUS study aims to evaluate etavopivat's efficacy in improving hemoglobin levels and reducing vaso-occlusive crises.
Trial design
The HIBISCUS study (NCT04624659) is a Phase 2/3 clinical trial designed to evaluate the efficacy and safety of etavopivat. The study enrolled 450 participants, including adults and adolescents with Sickle Cell Disease. Participants received either etavopivat tablets (low dose or high dose) or placebo tablets. The trial aims to assess how well etavopivat works compared to placebo to improve hemoglobin levels and reduce the number of vaso-occlusive crises.
What this means
The primary completion of the HIBISCUS study marks a significant step towards understanding the potential role of etavopivat in treating Sickle Cell Disease. With data collection now complete, the next phase involves comprehensive analysis of the collected efficacy and safety data. The results from this Phase 3 trial will be crucial for determining etavopivat's potential to improve outcomes for patients with this debilitating condition.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04624659, titled "A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)," was posted on 2026-02-06 on clinicaltrials.gov.